Starts in 1 month from now
LocationRoyal Museum for Central Africa, Tervuren
The fourth BE-ARMA* live event will comprise presentations about the ERA Action "Research Management Initiative – Enhancing the strategic capacity of Europe’s public research performing and funding organisations", and round table discussions about Artificial Intelligence from proposal to evaluation, challenges of blind evaluations, clinical trials and patient data, international collaboration. There will be certainly time for networking and a visit to the museum.
This information can be found on the announcement on the BE-ARMA website. The link to the agenda and registration tool is published on the BE-ARMA teams.
*BE-ARMA is a network of research managers and administrators in European funded projects, located in Belgium, from all type of organisations, facilitating peer-to-peer learning and exchange of best practices. Consult www.bearma.be for more details and how to join the community.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.